Plasmalight 148

Adult administration

Typically, 500-1,000mL is administered as an intravenous drip for adults. The administration rate is set at 200mL per hour. The dosage, rate, and duration of administration should be adjusted according to the purpose of use, age, body weight, concomitant therapy, clinical symptoms, and laboratory test results.

This medication is not suitable as the primary treatment for severe metabolic acidosis. It is also advised not to use it for the treatment of hypomagnesemia or severe potassium deficiency. When administering this medication, hypersensitivity reactions such as anaphylaxis may occur, so if symptoms appear, administration should be stopped immediately and appropriate treatment must be received. Patients at risk of hyperkalemia, especially those with poor kidney function or heart disease, should not use this medication; if unavoidable, potassium levels in the blood must be carefully monitored. Hypernatremia, hyperchloremia, and fluid overload may occur; therefore, caution should be taken when administering to patients at risk of these conditions, and regular monitoring of serum sodium and chloride levels, acid-base balance, and kidney function is necessary. Special attention should be given to children, elderly patients, post-operative patients, or patients on certain medications when administering this drug due to the high risk of hyponatremia, and immediate action should be taken if symptoms of hyponatremia occur. This medication contains sodium and potassium; thus, using it in conjunction with potassium-sparing diuretics or ACE inhibitors increases the risk of hyperkalemia, necessitating careful management of drug interactions. Women who are pregnant or breastfeeding should use this medication only after consultation with a doctor, as safety has not been established. Safety and efficacy in children have not been sufficiently proven; therefore, careful use while closely monitoring serum electrolyte levels is required. In case of overdose, metabolic alkalosis, hyperkalemia, hypermagnesemia, and fluid overload may occur, requiring immediate medical intervention. Before administration, check for turbidity or discoloration of the solution, ensure compatibility when mixing additives, and do not reuse any remaining solution after use. This medication can affect various electrolyte imbalances and fluid status, so it is important to regularly monitor blood glucose, electrolytes, fluid balance, and kidney function during administration.

Serious side effects

Anaphylactic reactions (hives, cold sweat), difficulty breathing, hives, cold sweat, hyponatremic encephalopathy, cerebral edema, pulmonary edema, peripheral edema, cardiac arrest, edema (peripheral and/or pulmonary), headache, seizures

Mild side effects

Warmth at the injection site, infection, venous thrombosis, phlebitis, exudation, fluid overload, injection site reactions (pain, burning sensation), tachycardia, palpitations, chest pain, chest discomfort, increased respiratory rate, flushing, congestion, weakness, mood changes, oral dryness, fever, hypotension, wheezing, chills, generalized urticaria and erythema, rash, vomiting, hypertension, tachycardia, chills

This medication should be stored in a sealed container to prevent contact with air and kept at room temperature. Avoid storage in overly hot or cold places, and it is safest to keep it in a cool place away from direct sunlight.

Appearance

A colorless, transparent liquid filled in plastic container for infusion.

Package unit

500ml/bag, 1000ml/bag